Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 April 2025 | Story Reuben Maeko | Photo Supplied
Dr Mutshidzi Mulondo
Dr Mutshidzi Mulondo, UFS academic in the Division of Public Health within the Faculty of Health Sciences at the UFS.

Dr Mutshidzi Mulondo, an academic in the Division of Public Health within the Faculty of Health Sciences at the University of the Free State (UFS), will make history when she becomes the first academic from the institution to be inaugurated into the Global Young Academy (GYA).

Dr Mulondo is one of two South Africans that are part of the 2025 cohort of incoming members who will be inaugurated to the sought-after prestigious Academy in Hyderabad, India. The other South African is Dr Mbuzeleni Hlongwa, a Senior Research Specialist at the Human Sciences Research Council.

The Global Young Academy is a network institution of the United Nations Scientific Advisory Board which allows young scientists from around the world to collaborate on research, set the global agenda, and contribute to global policies. The GYA develops, connects and mobilises young talent from six continents, and empowers young researchers to lead international, interdisciplinary and intergenerational dialogue and contribute to societal challenges. The GYA aims to elevate the voice of young scientists in evidence-informed and inclusive global, regional and national decision making.

The membership is comprised of passionate young scientists, typically who obtained their PhD degrees three to 10 years earlier, are between 30 to 40 years of age, and in the early stages of their independent academic careers. Members are selected for their scientific excellence and commitment to engage with society, and serve five-year terms.

 

Global Young Academy

“I feel honoured to be selected. The selection further cements the ingenuity of young African scientists and our ability to shape the global agenda. It allows us to envision a future together which leans towards empathy, kindness and unity,” said Dr Mulondo.

The Academy hopes to bridge the gap between established and new academics as well the gap between academics from the Global North and Global South. Further positioning academics from the south for interdisciplinary collaboration and publication in high impact journals to address complex and emerging challenges such as public health issues. The Academy selects young academics who display contribution to research, dedication to serving society and the ability to make an impact on the Academy’s community.

 

Aspirations in the academy

The recognition is testament that Africa is still producing globally competitive academics. This achievement is even better as it comes during the G20 presidency when Africa is showing what the developing world can produce. Coincidentally, Dr Mulondo, was one of the invited speakers at the G20 Research & Innovation Working Group, joining other selected young academics.

According to Dr Mulondo, who won the Zenith Global Health Award under the category ‘Mental Health and Well-being’ last year and was first runner-up in the category Emerging Leader at the South African Health Excellence Award. Academics from Africa have a responsibility to contribute to the development of the continent through evidence-based advice and solutions to policymakers. This membership allows young academics to stay in touch with global scientific trends and shifts in order to be better informed about resolving some of humanity’s most pressing crises.

She hopes to continue to advance public health strategies that prioritise mental health and health equity. With geopolitical complexities, climate changes and technological advancements shaping our future, the Academy allows for voices from the Global South to contribute to global policies and influence global policy decisions. “As a mentor and supervisor of master’s and PhD students in Public Health, I hope to contribute to ushering in a new generation of well-rounded public health researchers who are societally engaged.”

Prof Anthea Rhoda, UFS Deputy Vice-Chancellor: Academic, congratulated Dr Mulondo, saying the UFS is extremely proud of her. “Being selected as one of two South African scholars to the Global Young Academy demonstrates her dedication as a public health scholar passionate about making a difference in the health and well-being of society. Well done, on this great achievement.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept